Tak Hang Chan

University of Hong Kong — Hong Kong

Chemistry · Physical Sciences

68h-index16.5kcitations596works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Reactions(133), Asymmetric Synthesis and Catalysis(113), Synthetic Organic Chemistry Methods(83), Inorganic and Organometallic Chemistry(75), Chemical Synthesis and Analysis(72)

Publications595 total

Thermoresponsive Platinum(II) 2,6-Di(pyrid-2-yl)pyrazine Complexes with Unusual Aggregation Behavior upon Heating
Journal of the American Chemical Society·2025· 2 citedOpen Access
Fexinidazole optimization: enhancing anti-leishmanial profile, metabolic stability and hERG safety
RSC Medicinal Chemistry·2024· 4 citedOpen Access
Distinct molecular targets of ProEGCG from EGCG and superior inhibition of angiogenesis signaling pathways for treatment of endometriosis
Journal of Pharmaceutical Analysis·2023· 13 citedOpen Access
Identification of Binding Sites in the Nucleotide-Binding Domain of P-Glycoprotein for a Potent and Nontoxic Modulator, the Amine-Containing Monomeric Flavonoid <b>FM04</b>
Journal of Medicinal Chemistry·2023· 5 citedOpen Access
Supplementary Figure 1 from A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic &lt;i&gt;hTERT&lt;/i&gt; Repression in Human Breast Cancer Cells
2023Open Access
Supplementary Data from Disruption of SND1–MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Supplementary Figure Legend from A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic &lt;i&gt;hTERT&lt;/i&gt; Repression in Human Breast Cancer Cells
2023Open Access
Data from Disruption of SND1–MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Data from Disruption of SND1–MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Data from A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic &lt;i&gt;hTERT&lt;/i&gt; Repression in Human Breast Cancer Cells
2023Open Access
Supplementary Figure 1 from A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic &lt;i&gt;hTERT&lt;/i&gt; Repression in Human Breast Cancer Cells
2023Open Access
Data from A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic &lt;i&gt;hTERT&lt;/i&gt; Repression in Human Breast Cancer Cells
2023Open Access
Supplementary Figure Legend from A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic &lt;i&gt;hTERT&lt;/i&gt; Repression in Human Breast Cancer Cells
2023Open Access
Supplementary Data from Disruption of SND1–MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31
International Journal of Molecular Sciences·2023· 14 citedOpen Access
Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel
International Journal of Molecular Sciences·2022· 12 citedOpen Access
Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)2, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2)
International Journal of Molecular Sciences·2022· 9 citedOpen Access
Determination of (-)-epigallocatechin-3-gallate octaacetate and its metabolites in plasma of rats for pharmacokinetic study by ultra-performance-liquid-chromatography coupled to quadrupole-time-of-flight-mass-spectrometry
Frontiers in Pharmacology·2022Open Access
An In-Silico, In-Vitro and In-Vivo Combined Approach to Identify NMNATs as Potential Protein Targets of ProEGCG for Treatment of Endometriosis
Frontiers in Pharmacology·2021· 9 citedOpen Access
Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2)
Journal of Medicinal Chemistry·2021· 13 citedOpen Access
page 1 of 30Next →

Frequent Co-authors

Q. Ping Dou(9), Chao‐Jun Li(6), Weishi Miao(4), Kristin R. Landis‐Piwowar(4), Di Chen(4), Congde Huo(3), Vesna Milacic(3), P. BROWNBRIDGE(3), Wai Har Lam(3), Michael A. Brook(3), Kin‐Fai Chan(3), Sheng Wan(2), Huanjie Yang(2), Qiuzhi Cindy Cui(2), Z. Y. WEI(2), Aslamuzzaman Kazi(2), Larry M. C. Chow(2), Albert S. C. Chan(2), Lu Jiang(2), Shengbiao Wan(2)